Novartis to present five abstracts on Rhapsido at AAAI meeting

Novartis (NVS) will present data from five key abstracts evaluating the highly selective oral Bruton’s tyrosine kinase inhibitor Rhapsido in chronic spontaneous urticaria and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology, AAAAI, Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases. New analyses on the impact of Rhapsido on disease control and early symptom relief from the Phase III REMIX-1 and REMIX-2 trials in CSU will be presented. Additionally, the first presentation of Phase II FA data for remibrutinib, focusing on IgE-mediated peanut allergy, will be featured in an oral session. Plans are in progress to begin the Phase III program in FA in 2026.